IMCD Expands in Indian Pharmaceutical Market with Trichem Acquisition

IMCD, a global partner for speciality chemicals and ingredients, has acquired 100% of Trichem Healthcare Private Limited, Trichem Lifesciences Limited, and Chemistry & Health FZ LLC. Trichem, based in India, supplies high-quality active pharmaceutical ingredients, pharmaceutical intermediates, and formulation solutions, with annual revenue of approximately INR 1.7 billion (EUR 18 million). The acquisition enhances IMCD's portfolio and reinforces its position in the life-sciences industry.

Rotterdam, The Netherlands (June 19, 2025) – IMCD N.V. ("IMCD" or "Company"), a global leader in the distribution and formulation of specialty chemicals and ingredients, has announced the acquisition of 100% of the shares in Trichem Healthcare Private Limited, Trichem Lifesciences Limited, and Chemistry & Health FZ LLC. The acquisition aims to enhance IMCD's portfolio and strengthen its position in the life-sciences industry, particularly in India.

Founded in 1998 and headquartered in Mumbai, India, Trichem has built a strong reputation in the healthcare sector. The company supplies high-quality active pharmaceutical ingredients, pharmaceutical intermediates, and formulation solutions, and also provides regulatory assistance to customers serving the highly regulated pharmaceutical markets in India. With 36 employees, Trichem operates across India and the Middle East, generating annual revenue of approximately INR 1.7 billion (EUR 18 million) for the financial year ended 31 March 2025. About 33% of this revenue comes from commission income [1].

Narendra Varde, Managing Director of IMCD India, stated, "With India being a major supplier of the world’s generic drugs, this acquisition further enhances our portfolio, in particular with active pharmaceutical ingredients, and reinforces our position in the region’s life-sciences industry. Additionally, we are excited to welcome Trichem’s talented team, whose deep market expertise and strong industry relationships will be invaluable to IMCD."

Chetan Jain, Founder and Promoter of Trichem Group, added, "IMCD and Trichem share a common vision, strong entrepreneurial spirit, and commitment to building lasting partnerships. I am extremely proud of Trichem’s achievements over the past 27 years. Going forward with IMCD’s global presence, and our strong global principal partnerships, I am confident that this business will deliver immense value to our stakeholders."

The acquisition underscores IMCD's commitment to sustainable growth and its strategic focus on expanding its presence in the life-sciences sector. IMCD, based in Rotterdam, The Netherlands, is an expert solutions provider that adds sustainable value to the supply chain. With over 5,100 employees, IMCD realized revenues of EUR 4,728 million in 2024. IMCD N.V.'s shares are traded at Euronext Amsterdam (symbol: IMCD) and included in the Dutch ESG AEX index [2].

For further information, please visit www.imcdgroup.com.

References:
[1] https://www.ariva.de/aktien/imcd-group-aktie/news/imcd-acquires-trichem-to-accelerate-its-growth-in-the-11676567
[2] https://www.globenewswire.com/news-release/2025/06/26/3106088/0/en/IMCD-acquires-Trichem-to-accelerate-its-growth-in-the-pharmaceutical-markets-in-India.html